Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.6.5.2 extracted from

  • Nagata, M.; Kimura, T.; Suzumura, T.; Kira, Y.; Nakai, T.; Umekawa, K.; Tanaka, H.; Matsuura, K.; Mitsuoka, S.; Yoshimura, N.; Oka, T.; Kudoh, S.; Hirata, K.
    C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin (2013), Clin. Med. Insights Oncol., 7, 31-39 .
    View publication on PubMedView publication on EuropePMC

Application

Application Comment Organism
medicine natural polymor­phism C609T may affect amrubicin-related pharmacokinetics and clinical outcomes in lung cancer treatment. At a dose of 40 mg/m2, the T/T genotype exhibits a tendency toward a relationship with decreased concentrations of amrubicinol on days 2 and 4 of treatment. The genotype also shows a significant decrease of hematological toxicities Homo sapiens

Protein Variants

Protein Variants Comment Organism
C609T natural polymorphism which may affect amrubicin-related pharmacokinetics and clinical outcomes in lung cancer treatment. At a dose of 40 mg/m2, the T/T genotype exhibits a tendency toward a relationship with decreased concentrations of amrubicinol on days 2 and 4 of treatment. The genotype also shows a significant decrease of hematological toxicities Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P15559
-
-

Source Tissue

Source Tissue Comment Organism Textmining
lung lung cancer tissue Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
NAD(P)H + H+ + amrubicin
-
Homo sapiens NAD(P)+ + ?
-
?
NAD(P)H + H+ + amrubicinol
-
Homo sapiens NAD(P)+ + ?
-
?